Marker Therapeutics, Inc. — Director's Dealing 2016

Jul 19, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2016-07-18

Reporting Person: BONFIGLIO JOHN N (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-15	Common Stock	A	250000	$0.00	Acquired	250000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-18	Employee Stock Option (Right to Buy)	$0.475	A	750000	Acquired	2026-07-18	Common Stock (750000)	Direct

Footnotes

F1: Represents restricted stock award under the Company's 2014 Omnibus Stock Ownership Plan (the "Plan") granted in connection with the execution of employment agreement with the Company. The shares vest upon the earlier to occur of (i) the listing of the Company's common stock on a national securities exchange and (ii) the first anniversary of the grant date, or July 18, 2017, so long as recipient is employed with the Company.

F2: Represents option awarded under the Plan in connection with the execution of employment agreement with the Company. Of the 750,000 option shares awarded, 250,000 shares vest immediately, and the remaining options vest in 23 equal monthly installments of 20,833 shares, and the remaining 20,841 shares vest on the last day of the 24th month. The option exercise price is the closing price on July 15, 2016 the trading day immediately prior to the award date.